Given the critical role of CDK4/6 in HR + breast cancer and their increasing relevance in aggressive cancers such as triple-negative breast cancer (TNBC), we evaluated LA-CB1’s therapeutic potential in multiple cancer models. This evidence concerns the gene CNR1 and triple-negative breast carcinoma.